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Abstract This paper is the third in a series of reviews published in this issue resulting from
the University of California Davis Cardiovascular Symposium 2014: Systems approach to under-
standing cardiac excitation–contraction coupling and arrhythmias: Na+ channel and Na+ trans-
port. The goal of the symposium was to bring together experts in the field to discuss points of
consensus and controversy on the topic of sodium in the heart. The present review focuses on
cardiac Na+/Ca2+ exchange (NCX) and Na+/K+-ATPase (NKA). While the relevance of Ca2+
homeostasis in cardiac function has been extensively investigated, the role of Na+ regulation in
shaping heart function is often overlooked. Small changes in the cytoplasmic Na+ content have
multiple effects on the heart by influencing intracellular Ca2+ and pH levels thereby modulating
heart contractility. Therefore it is essential for heart cells to maintain Na+ homeostasis. Among
the proteins that accomplish this task are the Na+/Ca2+ exchanger (NCX) and the Na+/K+
pump (NKA). By transporting three Na+ ions into the cytoplasm in exchange for one Ca2+
moved out, NCX is one of the main Na+ influx mechanisms in cardiomyocytes. Acting in the
opposite direction, NKA moves Na+ ions from the cytoplasm to the extracellular space against
their gradient by utilizing the energy released from ATP hydrolysis. A fine balance between these
two processes controls the net amount of intracellular Na+ and aberrations in either of these two
systems can have a large impact on cardiac contractility. Due to the relevant role of these two
proteins in Na+ homeostasis, the emphasis of this review is on recent developments regarding the
cardiac Na+/Ca2+ exchanger (NCX1) and Na+/K+ pump and the controversies that still persist
in the field.
(Received 8 August 2014; accepted after revision 30 October 2014)
CorrespondingauthorM. J. Shattock: King’s College LondonBHFCentre of Excellence, TheRayne Institute, St Thomas’
Hospital, London SE1 7EH, UK. Email: michael.shattock@kcl.ac.uk
Abbreviations CKD, chronic kidney disease; CTS, cardiotonic steroids; EC, excitation–contraction; EGFR,
epidermal growth factor receptor; ESRD, end-stage renal disease; FRET, fluorescence resonance energy transfer; NCX,
Na+/Ca2+ exchanger; NKA, Na+/K+-ATPase (Na+/K+ pump); PKA, protein kinase A; PKC, protein kinase C; PLM,
phospholemman; RYR, ryanodine receptor; SERCA, sarco(endo)plasmic reticulum Ca2+-ATPase; SR, sarcoplasmic
reticulum; TMS, transmembrane segment; VSM, vascular smooth muscle.
M. J. Shattock and M. Ottolia contributed equally to this work.
C© 2014 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society DOI: 10.1113/jphysiol.2014.282319
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution
and reproduction in any medium, provided the original work is properly cited.
[The copyright line for this article was changed on 26 February 2016 after original online publication.]
1362 M. J. Shattock and others J Physiol 593.6
The Na+/Ca2+ exchanger – structure, function and
regulation
The session on ‘Na/Ca exchanger – structure, function and
regulation’ included Michela Ottolia, Karin Sipido, John
Bridge, Joshua Goldhaber, Andrew Edwards and Donald
Bers as speakers, discussion leaders and panelists. Below is a
summary of the current state of knowledge on the Na+/Ca2+
exchanger in cardiac ion homeostasis.
Molecular perspectives. The eukaryotic exchanger
protein, as exemplified by the mammalian cardiac
isoform NCX1.1 (indicated as NCX throughout the
review), is organized into ten transmembrane segments
(TMSs) (Liao et al. 2012; Ren & Philipson, 2013) with a
large cytoplasmic loop between TMSs 5 and 6 that plays
a regulatory role (Philipson et al. 2002). Ion transport is
associated with two regions of intramolecular similarity
named α repeats (Nicoll et al. 1996; Schwarz & Benzer,
1997; Shigekawa et al. 2002; Ottolia et al. 2005). They
consist of TMSs 2–3 and TMSs 7–8 and their connecting
links. The α repeats are highly conserved within the
exchanger family to the extent that they are deemed the
signature sequence of the Ca2+/cation exchanger class of
proteins (Lytton, 2007). Their role in ion translocation
has been confirmed by mutagenesis studies (Nicoll et al.
1996; Schwarz & Benzer, 1997; Shigekawa et al. 2002;
Ottolia et al. 2005) and recently by the structure of the
archaebacterial homologue NCX Mj (Liao et al. 2012)
(Fig. 1). In NCX Mj the two α repeats are packaged in
the core of the protein and form four ion binding sites
(three for Na+ and one of Ca2+) which are reachable
via two translocation pathways (Fig. 1). Essential amino
acids responsible for Na+ and Ca2+ ion binding are
conserved between the archaea and eukaryotic proteins
and accessibility data indicate that the portions of
α repeats are organized in a similar manner in the
mammalian cardiac exchanger (John et al. 2013). These
similarities are indicative of functional and mechanistic
conservation between NCX Mj and NCX. However,
enthusiasm is tempered by the low sequence similarity
between these two proteins outside the α repeats and the
usefulness of NCX Mj as a structural guide to investigate
the properties of the mammalian homologue should
be further investigated. For example, the links between
TMSs 2 and 3 and TMSs 7 and 8 of the α-repeats appear
to fold differently in the archaebacterial and mammalian
exchangers (Fig. 1). Previous accessibility mapping
studies using cysteine scanning mutagenesis and epitope
tagging (Nicoll et al. 1996; Iwamoto et al. 1999, 2000;
Shigekawa et al. 2002) indicate that these two portions
of the cardiac NCX form re-entrant loops while the
homologous regions in NCX Mj (Liao et al. 2012) lack
the re-entrant loop between TMSs 2 and 3 and have an
additional transmembrane segment between TMSs 7 and
8 (Fig. 1). Many of these residues are intimately involved
in ion transport as determined by mutagenesis studies.
Regulation of the mammalian NCX has been elegantly
demonstrated both at the functional and structural level.
Allosteric regulation of NCX by cytoplasmic Na+ and
Ca2+ ions occurs from within the large cytoplasmic loop
that separates TMS 5 from TMS 6 (Philipson et al.
2002). This regulatory loop is absent from the NCX Mj
structure. However, the structures of two regulatory
domains within this region of the eukaryotic exchanger
are now available (Hilge et al. 2006; Nicoll et al. 2006;
Besserer et al. 2007; Wu et al. 2009a,b, 2013). These two
contiguous stretches of residues bind cytoplasmic Ca2+
and are identified as Ca2+ binding domains 1 and 2,
respectively. They both adopt a β-sandwich fold organized
in a head to tail fashion separated by only 5–7 amino
acids. Binding of Ca2+ to these domains increases NCX
activity (Hilgemann et al. 1992; Matsuoka et al. 1995;
Ottolia et al. 2009) via molecular mechanisms not yet
fully understood. The role of Ca2+ regulation in vivo is
also uncertain as it is difficult to separate the effects of
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Figure 1. Molecular properties of the Na+/Ca2+ exchanger
The upper panels show the secondary topologies of the
archaebacterial (A) and eukaryotic (B) exchangers. The conserved
α-repeats (TMSs 2–3 and 7–8) are highlighted in darker shades. Note
that the loop connecting TMS2 and TMS3 is modelled as a P loop in
the eukaryotic NCX (B). The atomic structure of the archaebacterial
NCX (NCX_Mj) (Liao et al. 2012) is shown in C. The transmembrane
segments involved in ion transport are TMSs 2, 3, 7 and 8, coloured
in cyan, dark blue, yellow and orange, respectively. The cytoplasmic
ion translocation pathways of the cardiac exchanger have been
investigated by cysteine scanning mutagenesis (John et al. 2013). A
comparison between these data and the structure of NCX_Mj
suggests that these two proteins have similar architecture. This is
shown in D where the residues (shown in cyan and blue) of the
cardiac exchanger found sensitive to thiol modification were
mapped onto NCX_Mj inward structural model (shown as surface
representation as seen from the cytoplasmic side). The accessibility
data obtained from the eukaryotic exchanger correlates well with
the NCX_Mj structure.
C© 2014 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Ca2+ on the transport vs. regulatory sites. Recent evidence
suggests that while Ca2+ ions bind rapidly to these sites
at physiological levels (10–300 nM), its release is slow
suggesting that in vivo NCX may be persistently activated
during excitation–contraction (EC) coupling (Reeves &
Condrescu, 2003; Bers & Ginsburg, 2007; Giladi et al.
2010; Ginsburg et al. 2013; John et al. 2013). Na+ ion
regulation of NCX is less well studied. High cytoplasmic
Na+ inactivates theNa+/Ca2+ exchanger (Hilgemann et al.
1992) consistent with a state-dependent model, but the
mechanism is elusive. One hypothesis is that the binding
of Na+ to its transport site drives the exchanger into
an inactivated state (Hilgemann et al. 1992). However,
mutagenesis studies have shown that a region within the
large cytoplasmic loop is also involved in this process
(Matsuoka et al. 1995). Whether NCX modulation by
cytoplasmic Na+ is relevant to cardiac physiology remains
to be established since relatively high intracellular Na+
concentrations (20 mM) are required to significantly
inactivate NCX experimentally (Hilgemann et al. 1992;
Matsuoka & Hilgemann, 1994; Matsuoka et al. 1995).
Possibly, elevations in Na+ levels due to pathological
conditions such as heart failure (Despa et al. 2002b;
Despa & Bers, 2013) could influence NCX activity via
Na+-dependent inactivation. Further investigations into
NCX regulation by Na+ and Ca2+ are essential to
determine the physiological impact of NCX on heart
contractility.
Question or controversy: molecular perspectives
The crystal structure of the archaebacterial Na+/Ca2+
exchanger represents a milestone in the exchanger field
and revealed, unexpectedly, the absence of re-entrant
loops considered important for ion translocation in
the eukaryotic homologues. Due to the low sequence
similarity between the eukaryotic and archaebacterial
exchanger, further studies are required to elucidate the
properties of the mammalian NCX and to address the
following questions:
Does the mammalian NCX differ structurally from the
archaebacterial exchanger?
Evidence indicates that the mammalian NCX exists as
a dimer in the membrane (Ren et al. 2008; John et al.
2011) while the archaebacterial exchanger crystalizes as
a monomer. Does the oligomeric state of NCX affect its
function?
NCX in excitation–contraction coupling. The Na+/Ca2+
exchanger catalyses the countertransport of three Na+
and one Ca2+ using the energy of the Na+ gradient as
driving force. The cytoskeletal protein ankyrin B anchors
NCX to the membrane and the NKA may be part of this
complex suggesting the proximity of these two proteins
(Mohler et al. 2005). In cardiomyocytes NCX appears
widely distributed within the sarcolemma but there has
been some controversy concerning the proportion ofNCX
molecules located in T-tubules (Frank et al. 1992; Despa
et al. 2003), which would have considerable implications
for EC coupling. For example, confocal and internal
reflection imaging (Jayasinghe et al. 2009) show that 27%
of NCX labelling in rat myocytes is within 150 nm of
ryanodine receptor (RYR) puncta and that 45%of all NCX
labelling is concentrated within puncta. As the authors
explain these could be viewed as sites of concentratedCa2+
entry or exit and is consistent with a fraction ofNCXbeing
located within couplons, i.e. junctions. This is consistent
with earlier electrophysiological data suggesting that NCX
NKA
N
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RYR RYR RYR RYR RYR 
DiadicCleft Ca2+
Na+
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Figure 2. The Na+/Ca2+ exchanger primes the diadic cleft with Ca2+
The left panel shows the organization of the T-tubule and sarcoplasmic reticulum (SR) in an adult cardiac myocyte.
The specialized junction between the T-tubule and the SR is highlighted in the red box. This region is further
detailed on the right panel which depicts proteins important for excitation–contraction (EC) coupling (NKA, Na+/K+
pump; NCX, Na+/Ca2+ exchange; NaC, voltage-dependent Na+ channels; LCC, voltage-dependent Ca2+ channels;
RYR, ryanodine receptor). Activation of the voltage-dependent Na+ channels increases the Na+ concentration in
proximity of the Na+/Ca2+ exchanger, promoting its reverse mode. As a result, Ca2+ is transported into the diadic
cleft, priming EC coupling by facilitating the opening of RYRs by Ca2+ entering through voltage-dependent Ca2+
channels.
C© 2014 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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can sense subsarcolemmal Ca2+ during sarcoplasmic
reticulum (SR) release (Trafford et al. 1995; Weber et al.
2002); the dual time course of the NCX current during
caffeine-induced SR Ca2+ release in rat myocytes is
consistent with a fraction of NCX sensing early and high
local Ca2+ (in the dyad) and another being activatedwith a
delay (outside the dyad). Recent data indicate that L-type
Ca2+ channels and NCX within the dyadic cleft report
similar microdomain Ca2+ levels, with approximately
15% of all NCX located within close proximity to RyR
in pig ventricular myocytes (Acsai et al. 2011). Besides
results indicating that the triggering of SR Ca2+ release
flux requires NCX which is activated by triggering Ca2+
current (Sobie et al. 2008), there is also evidence indicating
that Na+ entry, via voltage-dependent Na+ channels, can
drive NCX into the reverse mode thereby priming the
dyadic cleft with a small amount of Ca2+, thus enhancing
triggering by voltage-dependent Ca2+ channels (Fig. 2)
(Larbig et al. 2010; Neco et al. 2010; Torres et al. 2010).
Abrupt inhibition of NCX-mediated Ca2+ extrusion can
instantaneously increase the frequency of Ca2+ sparks in
resting cardiac myocytes (Goldhaber et al. 1999).
Taken together, several lines of evidence suggest that
a fraction of NCX is within the junctional space of the
dyadic cleft. More studies to confirm the precise fraction
and location of NCX within the junctional region would
be of considerable value andwill doubtless be forthcoming
as themethods of high resolution confocal microscopy are
refined. The data obtained in rodent models further need
to be complemented with data from human and large
mammal models which have a low T-tubular density and
a large fraction of RyRs that are not within the dyadic cleft
(Louch et al. 2004). Importantly, in disease, reorganization
of the membrane structure and dyadic cleft occur and
affect NCX interaction with RyR (Biesmans et al. 2011).
The Na+/Ca2+ exchanger is themajor cardiac extrusion
mechanism for the Ca2+ that enters via voltage-dependent
Ca2+ channels with each beat. In conjunction with SR
Ca2+ uptake, Ca2+ removal by NCX allows myocytes
to relax. Concurrently, the coupled inward depolarizing
Na+ current is a fundamental component of the action
potential duration (Armoundas et al. 2003). Moreover,
outward shifts in both NCX and NKA current at higher
[Na+]i are important in determining action potential
repolarization and duration (Grandi et al. 2010). In these
roles, NCX is an important determinant of intracellular
Ca2+ and Na+ and hence contractility. Direct evidence
of the essential role of NCX in EC coupling comes from
ventricular-specific conditional knockouts of NCX. Two
mainadaptivemechanismsappear relevant for the survival
of these mice lacking an exchanger to provide Ca2+ efflux:
(i) a reduction in Ca2+ influx via voltage-dependent Ca2+
channels, and (ii) an increase in the gain in the EC
coupling; both of these are probably due to an increase
in Ca2+ within the dyadic cleft (Pott et al. 2005).
In addition tomaintaining both proper contraction and
Na+ homeostasis, NCX has also been implicated in the
generation of the pacemaker potential within the sino-
atrial node (SA node). Rhythmic spontaneous release of
Ca2+ from the SR via the RYR activates NCX resulting in a
net inward current facilitating depolarization helping the
pacemaker cells reach the threshold required for triggering
an action potential. Several models of mice lacking NCX
within the pacemaker cells have been generated with
the goal of determining the role of NCX in the genesis
of pacemaker activity (Gao et al. 2013; Groenke et al.
2013; Herrmann et al. 2013). Complete ablation of NCX
from both the atria and SA node tissue abolishes atrial
depolarization and sinus rhythm in an atrial-specificNCX
knockout (KO) mouse (Groenke et al. 2013). Isolated
SA node cells from these NCX KO mice are viable, but
they have no spontaneous action potentials despite an
intact funny current (If) through HCN4 channels. This
clearly demonstrates the importance of NCX in SA node
pacemaking.
Question or controversy: NCX in excitation–
contraction coupling
The role of NCX in priming EC coupling is well
documented but important questions remain:
Does NCX localize within the dyadic cleft? If so, what
is the ratio of NCX in the cleft to those outside?
Does NCX interact with other proteins involved in EC
coupling such as NKA or Na+ channels?
How does NCX prime the dyadic cleft to facilitate EC
coupling?
NCX and heart pathologies. Under physiological
conditions NCX ensures that intracellular Ca2+ is
removed after each beat to allow for proper relaxation
and cellular Ca2+ balance. However, common pathologies
promote Ca2+ influx via NCX leading to Ca2+
accumulation which can accelerate myocardial necrosis,
contractile failure and also trigger arrhythmias. This is
seen for example during reperfusion after an ischaemic
event when acidosis provokes Na+ overload by the
Na+/H+ exchanger and slows or even reverses NCX. This
example clearly demonstrates the tight coupling between
Na+ and Ca2+ homeostasis.
Alterations in NCX expression are also associated with
various cardiac pathologies including heart failure and
post-ischaemic cardiac injury. Heart failure, a highly pre-
valent condition world-wide, is mostly due to ischaemic
heart disease, valvular heart disease and hypertension.
It is associated with high mortality as a result of
contractile dysfunction and ventricular arrhythmia.While
evidence indicates that NCX expression and function are
significantly increased during the course of this pathology
(Studer et al. 1994; Dipla et al. 1999; Pogwizd et al. 1999;
C© 2014 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Hobai & O’Rourke, 2000), this is not a characteristic of
all stages of the disease nor in all types of heart failure
(reviewed in Sipido et al. 2002; Antoons et al. 2012).
The NCX function ultimately depends on prevailing Ca2+
and Na+ concentrations, as well as NCX distribution in
the membrane and surface-to-volume changes. Increased
NCX inward current in response to spontaneous SR Ca2+
release enhances afterdepolarizations, while the additional
Ca2+ efflux reduces SRCa2+ load. These events contribute
to the arrhythmogenicity and depressed contractility
associated with heart failure (Pogwizd et al. 1999; Pogwizd
& Bers, 2002). Additionally, an increase in intracellular
Na+ has been reported in cardiac myocytes during hyper-
trophy and heart failure with important implications for
NCX activity and thereby on contractility. The rise in
intracellular Na+ may also increase NCX reverse mode
promoting Ca2+ influx (Despa et al. 2002a; Despa & Bers,
2013). Although moderate Ca2+ influx could potentially
improve contractility linked toheart failure,Ca2+ overload
may contribute to arrhythmias and cell death.
Because of these important roles of NCX, modulation
of NCX function in heart failure has been suggested as
a therapeutic target (Sipido et al. 2002; Pogwizd, 2003;
Lee et al. 2005). For example, specific inhibitors for
NCX could represent an alternative strategy in arrhythmia
therapy (Antoons et al. 2012). However, pharmacological
manipulation of NCX is problematic due to the lack of
specific blockers. KB-R7943, long thought to be NCX
specific, is in fact quite non-specific and seems to block
other ionic currents (Reuter et al. 2002; Barrientos et al.
2009). Newer compounds such as SEA-0400 and SN-6 are
more specific over other ion currents and more potent
(Iwamoto et al. 2007; Niu et al. 2007). A unique and
potentially desirable property of such blockers is their
apparent preferential inhibition of NCX transport in
the Ca2+ entry (reverse) mode, as initially proposed for
KB-R7943 but later debated (Soma et al. 2006; Iwamoto
et al. 2007). It is likely that this apparent selectivity is
due to the asymmetric nature of the protein (i.e. different
sensitivity of NCX for Na+ and Ca2+ at the opposite sides
of the membrane) and the ionic conditions used to test
these drugs. Under circumstances of high intracellular
Na+, where reverse mode NCX activity dominates, NCX
may reside in a state more sensitive to drug-mediated
inhibition, thereby, leading to an apparentlymore efficient
block. It should also be noted, however, that in more
physiological conditions SEA-0400 will inhibit both
forward and reverse mode to an equal extent (Ozdemir
et al. 2008).
The development of a more selective inhibitor for NCX
has strong clinical relevance for its potential therapeutic
effects. However, the lack of structural information about
Figure 3. Diagram illustrating the relative distribution of Na+ pump α1 and α2 subunits in a cardiac
myocyte
The NKA resides and regulates intracellular Na+ and Ca2+ (via NCX) in both external sarcolemma and T-tubular
membranes. α1 is evenly distributed within the cells and is the dominant isoform providing around 88% of the
total Na+ pump current (Ip). α2 is 4–5 times more concentrated in the T-tubules compared to external sarcolemma
and provides only around 12–24% of the total Ip but up to 50% of the Ip in the T-tubules. Thus, it has been
suggested that α1 subunits may principally be involved in controlling bulk cytoplasmic Na+. Functional evidence
suggests that while both α1 and α2 subunits are expressed in T-tubular membranes, the possibility that the α2
subunit is relatively concentrated in the junctional areas (as shown above) remains to be structurally demonstrated.
Estimates of pump current are based on the measurements of Berry et al. (2007).
C© 2014 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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the mammalian cardiac NCX is a major hindrance to
achieving this goal and further studies are therefore
essential to advance this field. Despite these limitations
there have been a number of animal studies illustrating
efficiency of NCX block in arrhythmias (Antoons et al.
2012). A certain lack of selectivity and reduction of
L-type Ca2+ current (associated with NCX block) may be
advantageous, as recently shown (Bourgonje et al. 2013).
Question or controversy: NCX and heart pathologies
At present there are no specific drugs for NCX. This
prevents a full understanding of NCX’s role in normal
and pathophysiological conditions.
Additional structural information could help in
developing new drugs. Can a selective drug block Ca2+
entry while maintaining Ca2+ extrusion?
What post-translational modifications does NCX
undergo in pathological conditions that could alter its
mode of operation?
Is activation or blockade of NCX likely to be of benefit
in the treatment of heart pathologies?
The Na+/K+ pump – structure, function and regulation
In the session on ‘Na/K pump – structure, function and
regulation’ Julie Bossuyt, Jerry Lingrel, Michael Shattock,
Mordecai Blaustein, Jack Kaplan and Zi-Jian Xie were
speakers, discussion leaders and panelists. Below is a
summary of the materials presented and discussed in the
session.
While the Na+/Ca2+ exchanger is quantitatively one
of the main Na+ influx mechanisms in cardiac myo-
cytes it is just one of a plethora of membrane trans-
porters that utilize the energy in the trans-sarcolemmal
Na+ gradient to move ions, substrates, amino acids
and metabolites into or out of the cell. All of these
transport mechanisms dissipate the Na+ gradient. Thus,
the constant activity of theNa+/K+-ATPase (NKA, orNa+
pump) is essential for re-establishing and maintaining
this gradient. In cardiac and vascular smooth muscle the
principal isoforms of the NKA are α1 and α2 and their
physiological role is controlled both by their unique and
independent signalling pathways, and their discrete sub-
cellular distribution.
In cardiac muscle, the α2 subunit has been suggested to
play a specific subcellular role in preferentially regulating
Na+ in the dyadic cleft while the α1 subunit plays more
of a ‘housekeeping’ role regulating bulk cytoplasmic Na+
(Dostanic et al. 2005). In vascular smooth muscle and
skeletal muscle evidence also implicates the α2 subunit in
preferentially influencing contractile function (Juhaszova
& Blaustein, 1997; Zhang et al. 2005; Radzyukevich
et al. 2009). In the heart both isoforms (α1 and α2)
associate with, and are regulated by, the FXYD protein
phospholemman (PLM), with unphosphorylated PLM
exerting a tonic inhibition on ion pumping (Pavlovic et al.
2007; Bossuyt et al. 2009). When PLM is phosphorylated
(principally at Ser 63 and 68 by protein kinase C (PKC)
or at Ser 68 by protein kinase A (PKA)) this inhibition
is relieved and/or the pump is stimulated (Fuller et al.
2004; Despa et al. 2005). In this review we focus on recent
advances in the regulation of NKA by PLM and studies
elucidating the specific role of the α2 isoform in cardiac,
Arterial Wall
Inhibition/signalling
α1, α2, α3
Na/K ATPase 
adrenal  
gland 
Ouabain 
MBG 
Bufalin 
Telocinobufagin 
Short term: 
Inotropy 
Long term adaptation: 
Hypertrophy 
Fibrosis 
Diastolic dysfunction 
Arrhythmogenesis 
α1, α2, α3
Na/K ATPase 
Cardiac NKA
Inhibition/signalling
Short term: 
Vasoconstriction 
Long term adaptation: 
Arterial hypertension 
Muscle hypertrophy 
α1, α2, α3
Na/K ATPase 
Kidney NKA
Inhibition/signalling
Short term: 
Natriuresis 
Long term adaptation: 
Hypertrophy 
Glomerulosclerosis 
Brain 
High NaCl 
 Ouabain
ACTH
Angiotensin II
Cholesterol 
Figure 4. Proposed biosynthesis and
function of endogenous cardiotonic
steroids
Synthesis of endogenous cardiotonic
steroids occurs in the adrenal cortex from
cholesterol and is proposed to be under the
control of adrenocorticotropic hormone
(ACTH) and angiotensin II. These are
produced in response to high salt and the
resultant ouabain synthesis in the
hypothalamus. Acute effects of
endogenous cardiotonic steroids are
mediated via inhibition of the NKA and lead
to increased cardiac output, Na+ excretion
and vasoconstriction (NKA isoform-specific
effects in each tissue are shown in red).
Chronic exposure to cardiotonic steroids
leads to adaptational remodelling changes
of the affected tissue, possibly resulting in
hypertrophy, fibrosis, hypertension and
arrhythmogenesis. MBG, marinobufagenin.
Adapted from Pavlovic (2014).
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vascular and skeletal muscle, and the role of the NKA in
general in cardiovascular disease.
Molecular interactions between PLM and NKA.
Stoichiometry considerations. Several NKA crystal
structures have been resolved now, greatly advancing
our understanding of pump function and molecular
interactions of the pump complex (Morth et al. 2007;
Ogawa et al. 2009; Shinoda et al. 2009; Toyoshima et al.
2011; Kanai et al. 2013). In all the crystal structures
to date, the αβ complex, the minimal functional unit,
was associated with a tissue-specific, regulatory FXYD
protein (Kaplan, 2002; Jorgensen et al. 2003). Recently,
a pool of ‘pump-free’ PLM multimers was identified in
cardiac ventricle suggesting PLM expression is abundant
enough to saturate αβ complexes (Wypijewski et al.
2013). PLM oligomerization, specifically tetramerization,
is further supported by structural and fluorescence
studies in recombinant systems (Beevers & Kukol,
2006; Bossuyt et al. 2006; Song et al. 2011). These
PLM oligomers could represent an inactive storage
pool of PLM or may have non-pump-related functions
(e.g. form channels) but fluorescence resonance
energy transfer (FRET) data suggest that, like for
the phospholamban–sarco(endo)plasmic reticulum
Ca2+-ATPase (SERCA) system, the PLM–PLM and
PLM–NKA equilibria may be dynamically linked
(Bossuyt et al. 2006; Song et al. 2011). That is, PLM
phosphorylation shifts the PLM–NKA equilibrium
towards oligomers thereby relieving inhibition of the
pump and vice versa.
The Na+ pump as an αβFXYD unit (αβPLM for
cardiac NKA) with a 1:1:1 stoichiometry appears to
be the current consensus. Nonetheless, multiple studies
have claimed that NKA can exist as an oligomer
of multiple units ((αβFXYD)n) in native membranes
(reviewed by Taniguchi et al. 2001), but this idea remains
highly controversial and it is unknown whether NKA
oligomerization occurs in cardiac myocytes. Also, the
Kaplan group recently showed that multiple β subunits
can associate with α in the pump complex, suggesting
that NKA subunit composition may also not be so rigid
(Clifford & Kaplan, 2008, 2009). Finally, it is not known
whether other FXYD proteins are expressed in cardiac
myocytes at baseline or under stress (e.g. FXYD5 was
identified in cardiac homogenates; Lubarski et al. 2005).
NKA–PLM interactions. Physical interaction between
PLM and the NKA α1 and α2 isoforms was shown via
co-immunoprecipitation (Crambert et al. 2002; Fuller
et al. 2004; Bossuyt et al. 2005; Silverman et al. 2005)
and crosslinking (Lindzen et al. 2006) in heterologous
expression systems and cardiac myocytes. Crosslinking
(Lindzen et al. 2006) and SERCA homology predictions
(Sweadner & Donnet, 2001; Li et al. 2004) suggest that the
transmembrane domain (TM) of FXYDs could reside in
a groove formed by TM2, TM6 and TM9 of the NKA α
subunit. However, crystal structures show FXYD proteins
to be in proximity to, but not inside, this groove. The latter
may be only one of many physiological conformations but
mutational analysis showed that the E960 residue on NKA
TM9 and the F28 residue on PLM are critical for both
the functional effects on the pump and NKA–PLM FRET
(Khafaga et al. 2012). The co-immunoprecipitation was
not completely abolished by these mutations indicating
that additional PLM–NKA interaction sites contribute
to the robust physical association of PLM with NKA.
A similar approach showed that PLM phosphorylation
dramatically decreased NKA–PLM FRET without
eliminating co-immunoprecipitation (Bossuyt et al.
2006). This is consistent with NMR studies where PLM
phosphorylation increases the mobility of the cytosolic
tail which is normally tightly associatedwith the negatively
charged plasmamembrane (Franzin et al. 2007a,b; Teriete
et al. 2007). Thus, PLM phosphorylation alters the
PLM–NKA interaction but does not result in a complete
dissociation (as has been proposed for phospholamban
Asahi et al. 2001; Karim et al. 2006).
Question or controversy: stoichiometry interactions
Recent findings have called into question the dogma of
the Na+ pump complex as a functional heterodimer of
α and β subunits that can associate with tissue-specific
regulatory FXYD proteins.
Is the composition of the pump complex controlled
via dynamic regulation of subunit expression or
membrane abundance?Varying the compositionwould
have functional consequences but to what extent does
fine-tuning of the complex constituents occur? Or does
this only become relevant in pathological situations
such as heart failure?
If excess PLM is present in myocytes, possibly as PLM
multimers, then what is their function?
Conversely, do ‘alternative’ complexes such as αβn
or (αβ)n represent the pool of NKA with alternative
functional roles (e.g. signalling, adhesion)?
Differential roles of α1 and α2 in cardiac EC coupling.
Where are Na+ pump isoforms located? Of the four
known NKA isoforms only α1–3 are expressed in cardiac
muscle and their expression varies between species
(Hensley et al. 1992; Sweadner et al. 1994; McDonough
et al. 1996). The α1 isoform is both ubiquitous and
quantitatively dominant, with the majority of species
expressing significantly less, but functionally important,
amounts of α2. On a subcellular level, the α2 isoform
appears to be preferentially concentrated in T-tubular
membranes while the α1 isoform is relatively uniformly
distributed between T-tubular and external sarcolemmal
membranes (Berry et al. 2007; Despa & Bers, 2007; Swift
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et al. 2007; Bossuyt et al. 2009). It is worth noting
that the α1 subunit remains quantitatively comparable
and even the dominant isoform within the T-tubular
membrane (withα1:α2 density ratios reported as 1:1 (rat),
Despa & Bers, 2007, 3:2 (rat), Swift et al. 2007, and 4:1
(mouse) (Berry et al. 2007); however, the disproportionate
functional impact of the α2 isoform suggests α2 may
be further concentrated in the junctional regions of the
T-tubule – this has yet to be investigated (Fig. 3). This
preferential localization of the α2 subunit close to the
junctional SR has also been reported in both smooth
(Juhaszova & Blaustein, 1997) and skeletal muscle (Lavoie
et al. 1997).
Is there a preferential role for the α2 subunit in cardiac
EC coupling? The relative concentration of α2 in both
cardiac and smooth muscle in the specialized membranes
close to other ion translocators and the EC coupling
machinery, has led to the proposal that the α2 sub-
unit preferentially regulates the Na+ (and hence Ca2+)
concentration in a limited (junctional SR/T-tubular)
subcellular compartment that then strongly influences
contraction. In this model, the α1 subunit is proposed
to play more of a ‘housekeeping’ role regulating Na+ in
the bulk cytoplasmic compartment. Mice heterozygous
for the α2 isoform (α2(+/–)) have a hyper-contractile
phenotype (James et al. 1999), suggesting that Na+/K+
pumps containing the α2 subunit are functionally
linked to the NCX. Further evidence for this functional
compartmentation was provided by Dostanic et al. (2005)
and Despa et al. (2012) who compared the effects
of low-dose ouabain in wild-type hearts (expressing
the ouabain-sensitive α2 isoform) with that in hearts
expressing a geneticallymodifiedouabain-resistantα2 iso-
form (‘SWAP’ mice). Dostanic et al., using SWAP mice,
also demonstrated that the α1 isoform is physically and
functionally associated with the Na+/Ca2+ exchanger and
can also mediate inotropic responses to low-dose ouabain
(Dostanic et al. 2004).
Question or controversy: EC coupling
While there is little doubt that the α2 isoform is
important in the heart, a detailed understanding of
its role is still missing.
Is there a preferential role for the NKA α2 subunit in
EC coupling?
Within the T-tubule itself, are α2 isoforms further
concentrated in regions close to the junctional SR?
Differential regulation of cardiac α1 and α2. The
distinct distribution patterns of α1 and α2 suggest that
the respective isoforms would be exposed to different
signalling microdomains. Indeed, an early study in guinea
pig ventricular myocytes found an exclusive link between
PKA effects and NKA α1 isoforms, whereas PKC effects
were targeted to α2 isoforms (Gao et al. 1999). Subsequent
reports, however, found less divergent effects. Studies in
both Xenopus oocytes and SWAP mice found that PKA
activation increases the apparent Na+ affinity of both α1
and α2 (Bibert et al. 2008; Bossuyt et al. 2009), but in
detubulated mouse myocytes β-adrenergic effects were
limited to the α1 isoforms (Berry et al. 2007). FRET
experiments in cells from the human embryonic kidney
(HEK) cell line found that submaximalPKAactivationhad
less effect on the PLM–NKA α2 isoform interaction than
on the α1 isoform, indicating that the intrinsic sensitivity
to PKA regulation is slightly different for the two iso-
forms (Bossuyt et al. 2009). The PKC effects on NKA are
more complex. Even at the level of the overall effect there
are some discrepancies: most agree that PKC stimulates
NKA (Wang et al. 1998; Gao et al. 1999; Han et al. 2006;
Bibert et al. 2008; Fuller et al. 2009); however, inhibition
was also reported (Lundmark et al. 1999; Buhagiar et al.
2001; White et al. 2009). Some of these differences could
be due to which PKC isoform is engaged or the intra-
cellular Ca2+ level used in the experiment (since Ca2+ can
modulate PKC effects on NKA). The mechanism of the
increased pump activity also remains unclear as changes
in Vmax alone (Han et al. 2006; Bibert et al. 2008) or
both Vmax and Na+ affinity (Bossuyt et al. 2009) were
reported. These mechanistic differences could be due to
differential phosphorylation of PLM by PKA and PKC
(Han et al. 2006; Fuller et al. 2009). In oocytes, PKC
also affected only the turnover rate of the α2 isoforms
(Bibert et al. 2008). In SWAPmice on the other hand, PKC
increased the Na+ affinities (via phospholemman) of both
isoformswhile only increasing theVmax for the α2 isoform
(Bossuyt et al. 2009). Interestingly, in contrast to PKA,
PKC similarly affected PLM–NKA FRET for both NKA
isoforms. Thus, despite recent advances, the differential
regulation of NKA isoforms by protein kinases has not
been clearly established.
In addition to phosphorylation, other post-
translational modifications, such as glutathionylation
and palmitoylation of cysteine residues within the pump
complex, can regulate NKA function (Figtree et al. 2009;
Howie et al. 2013). Oxidant stress and modification of
NKA thiols has long been known to inhibit the NKA
activity (Shattock & Matsuura, 1993; Haddock et al.
1995) and, more recently, White et al. have shown
that angiotensin II-mediated oxidant stress can inhibit
Na+/K+ pump activity via a PKC and nitric oxide
synthase-dependent mechanism (White et al. 2009).
While the α, β and PLM subunits of NKA have all been
reported to be palmitoylated (Howie et al. 2013), and
the β subunit preferentially glutathionylated (Figtree
et al. 2009), at present whether regulation via such
thiol modification differs between α subunit isoforms is
unknown. Interestingly, a recent report from Gao et al.
shows that transmural gradients of angiotensin II may
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differentially regulate Na+/K+ pump function in response
to mechanical load (Gao et al. 2014).
TheNa+ pump in hypertrophy and heart failure. Evidence
and significance of Na+ dysregulation. Inmost mammalian
hearts with a long action potential, intracellular Na+
([Na+]i)is maintained at around 4–8 mM (Harrison
et al. 1992; Despa et al. 2002a). In mice and rats,
the combination of a high heart rate and short action
potential is associated with a higher Na+ of around
10–20 mM (Shattock & Bers, 1989; Despa et al.
2002a). As discussed earlier, the maintenance of this
large trans-sarcolemmal inward gradient is essential
for numerous transport and electrogenic processes
and its dissipation in various pathologies such as
ischaemia/reperfusion (Tani & Neely, 1989; Neubauer
et al. 1992), hypertrophy or heart failure (Pogwizd et al.
2003; Verdonck, 2003) is clearly detrimental. In hyper-
trophy and heart failure many aspects of EC coupling
are altered; however, in combination with these the
elevation in intracellular Na+ may contribute to the
negative force–frequency relationship, slowed relaxation
and arrhythmias (Pieske, 2002). Recently, O’Rourke
and colleagues have also shown that elevation of cyto-
plasmic Na+ can impair mitochondrial energetics (Liu &
O’Rourke, 2008; Kohlhaas et al. 2010; Liu et al. 2010).
Mitochondrial Ca2+ ([Ca2+]m) plays a key role in linking
ATP production to ATP demand (i.e. mechanical activity)
and as Ca2+ rises in the cell, so does [Ca2+]m; this activates
mitochondrial enzymes to step-upATP production (Liu&
O’Rourke, 2008; Kohlhaas et al. 2010). This relationship,
which cruciallymatches ATP supply to demand, is blocked
when cytosolic Na+ is elevated (Liu et al. 2010). The
rise in Na+ activates Na+/Ca2+ exchange in the inner
mitochondrial membrane and this keeps [Ca2+]m low
preventing ATP supply meeting demand, leaving the
heart metabolically compromised. Not only might this
contribute to the knownmetabolic insufficiency in failing
hearts but Kohlhaas et al. have shown that this mechanism
increases mitochondrial free radical formation in failing
hearts, further exacerbating injury (Kohlhaas et al.
2010).
While a component of the elevation of [Na+]i may
reflect an increase in Na+ influx (Despa et al. 2002b),
there is a large body of evidence showing that Na+/K+
pump function may also be compromised (Pogwizd
et al. 2003; Verdonck et al. 2003a,b; Boguslavskyi
et al. 2014b). Specifically in cardiac hypertrophy many
studies have shown that Na+/K+ pump function, and/or
expression, is reduced (Pogwizd et al. 2003; Verdonck
et al. 2003a,b; Bossuyt et al. 2005; Boguslavskyi et al.
2014b).
Role of PLM in hypertrophy and failure. Despite the
importance of PLM in regulating intracellular Na+, and
the considerable evidence suggesting that intracellular
Na+ is elevated in hypertrophied and failingmyocardium,
and contributes to diastolic dysfunction, the role of
PLM and its phosphorylation in the overloaded and
failing heart has not been systematically characterized.
Bossuyt et al. have reported hyper-phosphorylation of
PLMina rabbitmodel of volumeoverload-induceddilated
failure (Bossuyt et al. 2005) while El-Armouche et al.
(2011) have reported hypo-phosphorylation of PLM in
failing human hearts, attributable to down-regulation
of Inhibitor-1 and increased PP-1 phosphatase activity.
Recently, Boguslavskyi et al. (2014b) and Correll et al.
(2014) have reported a reduction in both PLM expression
and phosphorylation in mouse models of hypertrophy
that, in the Boguslavskyi study, has been directly related to
declining Na+/K+ pump function and intracellular Na+
elevation.
The lack of consensus regarding the PLM
phosphorylation status may reflect different stages
of the disease process or different animal models. Simply
reporting hypo- or hyper-phosphorylation of PLM also
does not distinguish between an effect that causally
influences the progression of the disease from one that is
simply a bystander – reporting dynamic disease-induced
changes in PKA and PKC signalling pathways. In order to
test this, Boguslavskyi et al. have used a mutant PLM3SA
knock-in mouse (in which PLM has been rendered
unphosphorylatable) (Boguslavskyi et al. 2014b). They
showed that preventing PLM phosphorylation in mice
subjected to aortic constriction further inhibits NKA
function, increases cellular Na+ overload and exacerbates
adverse hypertrophic remodelling. This suggests that
in heart failure, PLM hypo-phosphorylation in mice
is not simply a bystander effect (reporting dynamic
disease-induced changes in PKA and PKC signalling) but
is causally involved in disease progression.
Role of the α2 subunit in hypertrophy and failure. The
α2 subunit has been suggested to not only play a pre-
ferential role in normal EC coupling but also in the
pathological response to cardiac hypertrophy and heart
failure. In a recent study, Correll et al. have reported
that the over-expression of α2 (but not α1) preferentially
protects against adverse remodelling in the hypertrophic
heart and improves Ca2+ and Na+ handling. In this study,
the ‘forced’ over-expression of α2 leads to a reduction
in expression and phosphorylation of PLM and an over-
all increase in the Na+ sensitivity of the NKA. They
suggest that the α2 subunit is ‘less regulated by PLM’,
thus providing a mechanism by which α2 can efficiently
couple to NCX to maintain ion (and particularly Ca2+)
regulation. Adaptive increases in α2 expression are also
seen in mice expressing an unphosphorylatable form of
PLM (PLM3SA), perhaps allowing the normalization of
EC coupling despite an increase in the bulk cytoplasmic
Na+ concentration (Boguslavskyi et al. 2014b).
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Since cardiac remodelling and dysfunction in
heart failure are exacerbated by preventing PLM
phosphorylation (Boguslavskyi et al. 2014b), and α2
overexpression is protective (Correll et al. 2014), then
this raises the interesting possibility that Na+/K+ pump
stimulation may be therapeutically useful in heart failure
(Rasmussen & Figtree, 2007; Shattock, 2009) and, in
particular, isoform-selective α2 stimulation. Superficially,
this seems to fly in the face of 200 or more years of
digitalis use to treat heart failure. However, it would not
be the first time that counter-intuitive therapeutics prove
beneficial as demonstrated by the historic aversion to
negative inotropes in heart failure and the remarkable
recent success of β blockers. In fact, digitalis seems
to only provide symptomatic relief and, in the largest
trial of its kind, the Digitalis Investigation Group (DIG)
concluded that digoxin reduced hospitalization due to
worsening heart failure symptoms but had no long-term
effect on mortality (Hobbs, 1997). This issue is, however,
undoubtedly more complex, not least because of the pre-
sence of endogenous ouabains in heart failure patients and
the known ouabain–digoxin antagonism (see Blaustein,
2014 for review).
Question or controversy: heart failure
What do we need for the treatment of heart failure –
Na+/K+ pump inhibitors or stimulators?
The preferential role of the α2 subunit in EC coupling
may mean that an isoform-specific inhibitor might
be able to induce an ionotropic benefit WITHOUT
triggering Ca2+ overload and arrhythmias. Is it possible
to achieve an increase in SR Ca2+ load and positive
inotropy WITHOUT risking Ca2+ overload?
Conversely, it could be argued that the protective role
of the α2 subunit in heart failure suggests that an
isoform-specific (α2) stimulator might prevent Na+
and Ca2+ overload and limit adverse remodelling.
Isoform-specific roles in control of blood pressure. The
control of blood pressure, and specifically the aetiology
of primary hypertension is now recognized to have both
peripheral and central components. There is mounting
evidence that the misregulation of the NKA may
contribute to both.
Central role of α2 in regulation of blood pressure. While
primary hypertension involves the interplay of genetic and
environmental factors, such as high-salt intake, obesity,
insulin resistance, low physical activity levels and stress,
there is now increasing evidence that elements of such
hypertension may be neurogenic in origin (Huang et al.
2006; Esler et al. 2010). A number of studies have shown
that the level of Na+ in the cerebrospinal fluid (CSF)
is a critical factor contributing to the pressor response
induced by elevated dietary Na+ (Huang et al. 1998, 2001,
2004; Van Huysse et al. 2011). Van Huysse et al. (2011)
have shown that the rise in blood pressure in response
to CSF Na+ elevation is mediated by the central release
of an endogenous ouabain-like substance that specifically
targets the ouabain-sensitive α2 subunit of the NKA. The
cell types and CNS pathways involved in this signalling
pathway have yet to be identified. However, in the brain
the α2 NKA isoform is concentrated in the glia where,
coincidentally, 90%of brain angiotensinogen is also found
(Schinke et al. 1999). Since, upregulation of the glial
renin–angiotensin systemspecifically raises bloodpressure
(Morimoto et al. 2001, 2002), this cell type may be central
in the pressor response to Na+ load.
Question or controversy: blood pressure control –
central role of NKA
What is/are the cellular sources and identities of the
endogenous ouabain-like substances that mediate the
pressor response to Na+ elevation in CSF?
In human hypertension, does this pathway pre-
ferentially target the α2 NKA isoform in the CNS as
it does in mice?
Does this offer a novel therapeutic target for the
treatment of primary hypertension?
Peripheral role of α2 in the regulation of blood pressure.
In addition to a central role for the NKA in blood pressure
control, the activity of the Na+/K+ pump can also locally
regulate both endothelial and vascular smooth muscle
(VSM) function. The NKA in VSM, as in myocardial
cells, sets and maintains the Na+ and K+ electrochemical
gradient and, in this way, modulates the activity of other
membrane ion channels and signalling pathways (Shelly
et al. 2004; Zhang et al. 2005). The relatively high input
impedance of VSM cells also means that the electro-
genic pump can theoretically directly and substantially
modulate membrane potential (and hence Ca2+ influx)
with activation of the pump causing hyperpolarization
and relaxation, and inhibition causing depolarization and
vasoconstriction (Casteels et al. 1977; Quinn et al. 2000;
Burns et al. 2004; Molin et al. 2005). However, the extent
to which electrogenic NKA activity in vascular smooth
muscle contributes to membrane potential varies between
experimental preparation and vascular beds. Selective α2
inhibition by low-dose ouabain also can mediate vaso-
constriction in the absence of changes in membrane
potential. Thus, while NKA activity can undoubtedly
modulate vascular tone, in many studies it is difficult to
dissociate effects arising from NKA-induced changes in
membrane potential from those induced by changes in ion
channels or secondary to changes in local ion gradients,
NCX activity etc. The situation is further complicated
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by studies showing that the effects of NKA inhibition
or stimulation differ between intact vessels and those in
which the endothelium has been denuded – suggesting
that both smooth muscle and endothelial NKA activity
can modulate vascular tone in intact tissues (see below).
As in other tissues the vascular NKA is expressed as
a heterodimer composed of a catalytic α subunit and a
glycosylated β subunit (Lingrel & Kuntzweiler, 1994). Of
the four known α isoforms (α1–4) only α1 and α2 were
found in VSM cells (Shelly et al. 2004; Pritchard et al.
2010). These isoforms have different cellular distribution,
expression and functional significance. In VSM cells the
α1 isoform is by far the most abundant and is thought to
play a ‘house-keeping’ role controlling bulk cytoplasmic
Na+ (Juhaszova & Blaustein, 1997; Weston et al. 2002).
In rodents, this α1 isoform is relatively insensitive to
ouabain. The α2 ouabain-sensitive isoform, while much
less abundant, has a highly localized cellular distribution
and is suggested to play a role in regulating Na+ in micro-
domainswithpreferential access toothermembrane trans-
porters (Juhaszova & Blaustein, 1997; Shelly et al. 2004;
Pritchard et al. 2010). The close association between the
α2 subunit, NCX and the intracellular SR membrane has
been suggested to give the α2 subunit a preferential role
in regulating Ca2+ (and hence constriction) in VSM cells
(Juhaszova & Blaustein, 1997; Arnon et al. 2000; Lee et al.
2006; Linde et al. 2012). Recently it has been shown that
NKA and Ca2+-handling proteins form a functionally
coupled unit where the concentration of Na+ in a sub-
cellular microdomain modulates submembrane Ca2+ and
hence SR Ca2+ load (Matchkov et al. 2007; Pritchard
et al. 2010). Reduction of NKA activity (specifically of
α2) by pharmacological inhibition or transgenesis leads
to enhanced agonist-induced vascular contractility and
myogenic tone (Zhang et al. 2005). Matchkov et al.
showed that α2, through modulation of local Ca2+, is
very important in gap junction coupling between VSM
cells and hence affects vasomotion and the spread of vaso-
constriction and relaxation (Matchkov et al. 2007, 2012).
There is also a large body of evidence showing that NKA
is important for NO- and endothelium-derived hyper-
polarizing factor (EDHF)-dependent responses (Gupta
et al. 1994; Sathishkumar et al. 2005; Leung et al. 2006;
Dora et al. 2008; Matchkov et al. 2012). Furthermore, the
α2 subunit is present at myo-endothelial junctions where
local increases of K+ concentration (due to the opening of
endothelial Ca2+-activated K+ channels) can activate the
Na+/K+ pump and induce VSM cell hyperpolarization
and relaxation (Dora et al. 2008).
Given the involvement of NKA (in particular α2) in
the regulation of myogenic tone, vasomotion, cell-to-cell
coupling, and NO- and EDHF-dependent relaxation
it is perhaps not surprising that NKA activity may
be an important modulator of blood pressure (BP)
in vivo. Circulating endogenous ouabain, for example,
has been shown to be involved in hypertension in
both animals and humans (see below) (Manunta et al.
1999; Schoner, 2002). Furthermore, in mice expressing
ouabain-resistant α2 NKA, Dostanic et al. showed that
ouabain-induced hypertension is mediated by the α2 sub-
unit (Dostanic et al. 2005). Further experimentswith these
mice revealed the importance of ouabain-binding sites on
NKA in ACTH-induced hypertension (Dostanic-Larson
et al. 2005; Lorenz et al. 2008). Results obtained from
other genetic models with global down-regulation or
over-expression of NKA demonstrate that the activity
of NKA has a major impact on BP (Zhang et al.
2005; Pritchard et al. 2007). Interestingly, in mice with
cardiovascular-specific knockout of α2, basal BP was not
affected, but thehypertensive response toACTHtreatment
was blunted (Rindler et al. 2011).
In the vasculature, as in cardiac and skeletal muscle,
NKA is associated with FXYD1 (phospholemman)
(Palmer et al. 1991; Rembold et al. 2005). Dey et al.
demonstrated that PLMphosphorylation byPKCactivates
the α2 isoform pulmonary artery smooth muscle cells
(Dey et al. 2012). Recently, Boguslavskyi et al. have
shown that PLM phosphorylation is critically important
in modulating the constrictor response of aortic smooth
muscle to phenylephrine and the relaxing effects of an
NO donor (Boguslavskyi et al. 2014a). In the heart,
Pavlovic et al. have shown that NO stimulates NKA
via PKC-mediated PLM phosphorylation (Pavlovic et al.
2013). Whether similar pathways exist in the vasculature
is yet to be determined.
In summary, direct (endogenous cardiotonic steroids,
local K+) or indirect (PLM dependent) regulation of
vascular NKA activity affects myogenic tone through
altering Na+ and Ca2+ homeostasis and/or stimulating
Src-dependent signalling (see below) which significantly
influences blood pressure in vivo.
Question or controversy: blood pressure control –
vascular smoothmuscle
Does the NKA (and specifically the α2 subunit) play a
role in regulating vascular tone and if so, are these effects
mediatedby electrogenicNKAtransport and changes in
membrane potential or by changes in transmembrane
ionic concentrations?
What are the relative roles of smooth muscle vs. end-
othelial NKA in regulating tone?
Is vascular smooth muscle NKA regulated by
phospholemman and, if so, via which signalling
pathways?
Is this signalling–PLM–NKA–tone pathway defective
in hypertension and/or does it provide a therapeutic
target for the treatment of hypertension?
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Na+/K+ pump function and skeletal muscle. Skeletal
muscle fatigue. While many other mechanisms (such
as Pi accumulation, acidosis, ATP depletion, generation
of reactive oxygen species etc.) have been implicated
in fatigue (see Allen et al. 2008 for review), there is
substantial evidence that extracellular K+ accumulation
(and the associated disruption of intracellular Na+ and
K+ concentrations) is central to this process (Medbo
& Sejersted, 1990; Juel et al. 2000; Clausen, 2003;
Allen et al. 2008). The NKA plays a central role in
limiting extracellular K+ accumulation during exercise
(Clausen, 2003). Interventions that stimulate the pump
(such as the β2-adrenoceptor agonist salbutamol) can
decrease K+ accumulation and limit fatigue (Clausen,
2003), while interventions that inhibit the pump (such
as ouabain) increase K+ accumulation and exacerbate
fatigue (Nielsen & Clausen, 1996). It is now widely
accepted that the increased activity of the NKA during
exercise ‘protects’ skeletal muscle against fatigue during
exercise (Juel et al. 2000; Clausen, 2003). One of the
strongest drivers for activation of the Na+/K+ pump is the
elevation of intracellular Na+. However, it is also clear that
sympathetic stimulation (which inevitably accompanies
exercise in vivo) also directly activates the pump and can
increase its basal turn-over by up to 20-fold (Allen et al.
2008). This appears to be particularly important when
extracellular K+ is elevated (Nielsen & de Paoli, 2007).
An increasing number of studies have implicated PLM
as the link between cell signalling and exercise-induced
NKA stimulation (Thomassen et al. 2010, 2011, 2013;
Benziane et al.2011). PLMphosphorylation is increasedby
exercise via a PKCα-dependent mechanism (Thomassen
et al. 2011) possibly in response to intracellular Ca2+
elevation, although the exact signalling pathways involved
have yet to be determined.
Role of the α2 subunit. While quantitatively the α1
subunit dominates cardiac muscle, in skeletal muscle up
to 87% of total NKA expression is estimated to be α2
(He et al. 2001). As in the heart, α2 in skeletal muscle
appears to preferentially play a key role in regulation of
contraction and protection against fatigue. Radzyukevich
et al. (2013) used a skeletal muscle-specific α2 knockout
to demonstrate that α2, but not α1, is responsible for
acute upregulation of NKA activity and protects skeletal
muscle against fatigue (Radzyukevich et al.2013). This and
other studies also show that the functional α2 subunit is
preferentially located in the T-tubules and it is potassium
regulation within the T-tubular lumen thatmay be critical
in determining fatigue (Lavoie et al. 1997; Williams et al.
2001; Heiny et al. 2010). A large fraction of skeletal muscle
α2 may also be resident in submembrane vesicles readily
available for trafficking to and from the plasmamembrane
in response to receptor stimulation or demand (Hundal
et al. 1992; Al-Khalili et al. 2003).
Question or controversy: skeletal muscle
Does the phosphorylation of phospholemman regulate
skeletal muscle NKA and, if so, via which signalling
pathways?
Does dysregulation of these pathways contribute to
muscle fatigue?
Endogenous cardiotonic steroids. Realization that
cardiotonic steroids (CTS) are present in nanomolar
concentrations in the serum of experimental animals and
humans has intensified research into their physiological
and pathophysiological roles over the last 20 years
(Hamlyn et al. 1982; Bagrov et al. 1998; Gallice et al.
1998; Gonick et al. 1998; Manunta et al. 1999; Harwood
et al. 2001; Periyasamy et al. 2001; Komiyama et al.
2005; Kennedy et al. 2006; Fedorova et al. 2009; Li et al.
2010). Interestingly, a recent study using a highly sensitive
UPLC–MS–MS technique failed to detect ouabain per se in
human plasma suggesting that the CTS detected in other
studies using radioimmunoassays represent compounds
that are structurally similar, but not identical, to ouabain
(Baecher et al. 2014). CTS are divided into two structurally
distinct groups, cardenolides (ouabain-like compounds
and digoxin) and bufadienolides (marinobufagenin,
bufalin and telocinobufagin). Evidence is accumulating
that most CTS are synthesized from cholesterol in the
adrenal glands and possibly hypothalamus (Laredo et al.
1995; Dmitrieva et al. 2000; Murrell et al. 2005). The
trigger for biosynthesis initiation is complex, with serum
concentrations of CTS increasing in response to kidney
dysfunction (Komiyama et al. 2005; Stella et al. 2008;
Tian et al. 2010), volume expansion (Manunta et al.
2006), salt accumulation in the brain (Huang et al.
2004), adrenocorticotropic hormone, angiotensin II,
vasopressin, and phenylephrine (Laredo et al. 1995;
Shah et al. 1999). Growing evidence suggests that CTS
secretion is involved in the pathogenesis of a number of
diseases such as hypertension, pre-eclampsia and uraemic
cardiomyopathy.
Cardiotonic steroids in blood pressure control. The
mechanisms that govern CTS-mediated hypertension
development have not yet been fully elucidated; however,
evidence is accumulating that in response to high salt
intake, a ouabain-like compound is secreted by the hypo-
thalamus (Murrell et al. 2005), whereas both ouabain
and marinobufagenin are secreted by the adrenal glands
(Laredo et al. 1995; Dmitrieva et al. 2000) and that
this leads to both central and peripheral blood pressure
elevation (Fig. 4). Specifically, high salt intake elevates both
plasma and cerebrospinal fluid Na+ and this induces the
secretion of CTS by the adrenals and the hypothalamus
(Huang et al. 2004). Intracerebroventricular infusion of
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Na+-rich cerebrospinal fluid (Van Huysse et al. 2011) or
ouabain (Huang et al. 2004) increased sympathetic nerve
activity, heart rate and blood pressure in rodents and these
effects were partially reversed by Digibind (anti-digoxin
Fab
R©
fragments). On the other hand, chronic intravenous
infusion of ouabain ormarinobufagenin at concentrations
comparable with in vivo plasma levels lead to an increase
in arterial pressure and cardiac hypertrophy (Pamnani
et al. 1994; Ferrandi et al. 2004; Kennedy et al. 2006).
Furthermore, hypertension induced either by salt loading,
ouabain infusion or pre-eclampsia is reduced by immuno-
neutralization with anti-CTS antibodies (Fedorova et al.
2002, 2007) or CTS antagonists rostafuroxin (Ferrari
et al. 2006) and resibufogenin (Horvat et al. 2010). It
is important to emphasize that ouabain binds to the
Digibind with high affinity, whereas marinobufagenin
binding affinity is lower (Pullen et al. 2004) suggesting
that aouabain-like substance is thedominantCTS inblood
pressure regulation. Whereas the effects of brain-derived
endogenous ouabain require further characterization,
plasma ouabain produced by the adrenal glands can
contribute to acute vasoconstriction via inhibition of the
α2 sodium pumps in the smooth muscle, as discussed
in the previous section ‘Isoform-specific roles in control
of blood pressure’. Interestingly, 3 days of salt loading in
healthy individuals did not result in a change in blood
pressure (Manunta et al. 2006) suggesting that acute
salt-loading in a healthy individual has no pathological
consequences. However, it is clear that during chronic
salt loading or chronic ouabain infusion, hypertension
persists. It is likely that this is mediated via a combination
of chronic elevation of brain Na+, leading to increased
sympathetic nerve activity, and the direct effects of end-
ogenous ouabain on the smooth and cardiac muscle,
potentially resulting in increased cardiac output, increased
total peripheral resistance and thus elevation in blood
pressure. Furthermore, reportedCTS-mediated activation
and internalization of the Na+/K+–Src–epidermal growth
factor receptor (EGFR) complex (Liu et al. 2002, 2004,
2005) as well as up-regulated arterial expression of the
NCX1, SERCA2 and TRPC6 (Blaustein et al. 2012; Pulina
et al. 2013) could contribute to arterial remodelling of
the affected tissue and thus leading to established hyper-
tension. Whereas both ouabain and marinobufagenin
have been implicated in the regulation of blood pressure
and hypertension development, most of the currently
available data imply that ouabain is the dominant
CTS. Interestingly, digoxin has been shown to oppose
ouabain-induced hypertension in rats (Kimura et al.
2000; Manunta et al. 2000) and possibly even in humans
(Abarquez, 1967). Song et al. (2014) report that low doses
of digoxin can antagonize the effects of ouabain, possibly
explaining the recently reported beneficial effects of low
doses of digoxin therapy in heart failure patients (Ahmed
et al. 2006).
Question or controversy: endogenous cardiotonic
steroids
What is the biological significance of the diversity of
endogenous CTS?
Do individual CTS play specific roles in the
development of cardiovascular dysfunction?
Can we exploit knowledge of the antagonism between
CTS molecules to therapeutic advantage?
Cardiotonic steroids in chronic kidney disease. It has
been evident for many years that patients with chronic
kidney disease (CKD) and end-stage renal disease (ESRD)
are at increased risk of developing cardiovascular disease
(Tyralla & Amann, 2002; Best et al. 2004). Renal
failure results in a cardiomyopathy characterized by left
ventricular hypertrophy, reduced ejection fraction, myo-
cardial fibrosis and arrhythmias (Tyralla & Amann, 2002;
Best et al. 2004). Although the cause of cardiomyopathy
development is likely to be multifactorial, McMahon and
colleagues have observed elevated diastolic intracellular
Ca2+ (due to compromised NCX activity) in the hearts of
rats with impaired renal function (McMahon et al. 1996,
2002, 2006; Donohoe et al. 2000).
Considering that serum levels of ouabain,
telocinobufagin and marinobufagenin are substantially
elevated in patients with ESRD (Komiyama et al. 2005;
Stella et al. 2008) and animals with CKD (Kennedy et al.
2006, 2008), it is reasonable to propose that CTS-mediated
Na+/K+ inhibition and subsequent increase in intra-
cellular Na+ could be the mechanism responsible for
the observed myocardial Ca2+ overload and could
explain contractile dysfunction, negative force–frequency
relationship, increased susceptibility to arrhythmias and
left ventricular hypertrophy. Ca2+ overload in the smooth
muscle could also lead to the development of hypertension
as discussed in the previous section. In a rat model of
CKD, Pavlovic et al. have shown that cardiac Na+/K+
pump is inhibited and that this inhibition is attenuated
by the removal of CTS using DigiFAB
R©
(Pavlovic, 2010).
On the other hand, Liu and colleagues have proposed
an alternative model of CTS-mediated cardiomyopathy
development. This model proposes that a fraction of
Na+/K+ pump subunits are localized in the caveolae and
are not involved in transport of Na+ and K+ ions but
instead act as receptors for CTS (Pierre & Xie, 2006).
These ‘inactive’ pumps are physically associated with
other key signalling proteins such as EGFR and Src (Wang
et al. 2004; Liang et al. 2007). Binding of the CTS leads to
activation of hypertrophic and fibrotic signalling cascades
via Na+/K+–Src extracellular signal-regulated kinase (Li
et al. 2010), independently of changes in intracellular
Na+ and Ca2+ (Liu et al. 2000). This alternative signalling
pathway does not account for the reported Na+/K+ pump
inhibition that can be reversed by anti-CTS antibodies
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in patients with diabetes (Bagrov et al. 2005) or ESRD
(Periyasamy et al. 2001), nor the accompanying increases
in intracellular Na+ and Ca2+ reported by other groups
(Peng et al. 1996; Dong et al. 2004; Andrikopoulos et al.
2011). Na+/K+ pump inhibition via CTS alone can
explain the cardiovascular dysfunction observed in CKD
patients, whereas the signalling model can only account
for the hypertrophy and hypertension development.
Whether CTS induce hypertrophic growth in the heart
via the ionic or signalling pathway remains to be resolved,
however, the weight of evidence in support of both
pathways makes it likely that they act in conjunction with
each other.
Question or controversy: CKD-induced cardio-
myopathy
Although the CTS binding site is highly conserved
across the evolutionary spectrum (Lingrel, 2010), rats
and mice possess an Asn122His substitution in their
NKA α1 isoform, making it less sensitive to CTS (Price
& Lingrel, 1988). Considering that most studies are
conducted in rat and mouse, a question of relevance
of some of the data to human physiology requires
investigation.
The relative contribution of the CTS signalling vs.
effects on ion transport of the NKA in CKD and hyper-
tension have yet to be determined.
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